AbbVie said that its new hepatitis C drug regimen has been given a breakthrough therapy designation by the Food and Drug Administration, putting it on the fast track for potential approval in the United States.
Will we see baby boomers lining up to be tested for the liver-destroying virus hepatitis C, as the U.S. Centers for Disease Control and Prevention recommended Thursday.
Gilead Sciences, after paying $10.8 billion for the developer of an experimental hepatitis C drug, will soon give investors a better sense of whether its largest-deal ever is going to pay off.
Beginning next week, Gilead will release data from dozens of patients who have tried the medicine, providing the most complete evidence yet about its prospects for treating 170 million people who are infected with the virus globally.
Rival hepatitis C drugs from Merck & Co and Vertex Pharmaceuticals are effective in patients also infected with HIV, the virus that causes AIDS, according to data released on Tuesday. The Vertex drug had the more impressive results, the data showed.